ENP Newswire -
Release date- 19062014 - Scientists developing a material that mimics bone have won a major venture prize that takes their pioneering product a step closer to being used in patients.
The SIRAKOSS MaxSi Graft technology which produces purely synthetic material, with no variability in performance, has the potential to treat many thousands of patients who need spinal fusion surgery for back pain, or repairs for traumatic bone injuries.
This innovation has won SIRAKOSS - an innovative medical device company based in
'Funding from the prize will help bring our unique synthetic bone material closer to market. This could help the many hundreds of thousands of people who need bone grafts or bone repairs following the type of fractures suffered in road accidents which can be difficult to heal.'
Figures for 2012 show there were 1.7 million clinical procedures using bone graft substitutes in the
Professor Gibson and the SIRAKOSS team have spent eight years developing and refining the MaxSi Graft technology which has a unique chemical composition and scaffold structure for achieving bone repair and fusion.
'We are taking a different approach to the synthesis of our material which we believe will make it more successful than other artificial bone products currently available to surgeons. Our product contains no human or animal proteins which removes the risk of potential batch-to-batch variability in performance. Also, because it's made in the lab, it could be available in endless supply.
'Currently, patients who need bone grafts will frequently have bone grafted from elsewhere in their body or from bone harvested from a cadaver. Both of these types of grafts have their issues,' explained Professor Gibson.
'You may have an elderly patient going into hospital for an operation on their back which uses bone taken from their pelvis - a process called autografting. The patient then has two operations to recover from, which is far from ideal. Also more than 30% of patients suffer long term chronic pain at the previously healthy site where the bone was harvested.
'Cadaver bone also has its problems - it has the potential for disease transmission and is of variable quality and efficacy.'
The Prize will progress efforts in achieving regulatory approval for clinical use. The aim is to MaxSi Graft technology approved for use in patients in two years' time.'
Most Popular Stories
- Bently Creates Alabama Small Business Commission
- Bolivar Appointed to NSHMBA National Board
- When to Say No to Investors, Yes to Mentors
- SBA Kicks off Hispanic Heritage Month
- Rosneft Growth Slowed by Western Sanctions
- Duke Energy, Strata Partner on Big Solar Project
- Ukraine Offers Temporary Autonomy to Rebel-held Areas
- Thousands Risk Losing Health Care Aid
- Lindsay Lohan Claims She Handled Whitney Houston's Body Bag
- Cat Stevens Touring U.S., First Since 1970s